GILD - Gilead Sciences, Inc.
80.05 +0.10 (0.13%)
Pre-Market: 7:06AM EDT
| Previous Close | 81.17 |
| Open | 81.13 |
| Bid | 80.00 x 500 |
| Ask | 80.43 x 600 |
| Day's Range | 79.55 - 81.21 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 7,377,562 |
| Avg. Volume | 9,323,824 |
| Market Cap | 104.41B |
| Beta | 0.90 |
| PE Ratio (TTM) | 8.68 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.56%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Market Realist•6 hours ago
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
- Barrons.com•20 hours ago
[$$] More Biotechs That Can Beat Q3 Views
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
- Forbes•20 hours ago
Berkshire Hathaway And 6 Other Piggyback Stocks To Profit From
Seven buy list stocks from some of the greatest value investors.
- Zacks•22 hours ago
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
- Investor's Business Daily•yesterday
6 Top Biotech Companies In Innovation Earn Recognition In New Awards
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
- Investor's Business Daily•yesterday
Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
- The Wall Street Journal•yesterday
[$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
- Zacks•4 days ago
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
- InvestorPlace•4 days ago
It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
- InvestorPlace•4 days ago
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
- Motley Fool•4 days ago
3 Healthcare Value Stocks
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
- Zacks•5 days ago
Non-Alcoholic Steatohepatitis 2017 Progress Update
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- Investopedia•5 days ago
Top 5 Biotech Stocks for 2017
Biotech can be risky, but these top biotech stocks have stable track records.
- Investopedia•5 days ago
Celgene, Biogen Are Poised to Break Out: A Technical View
After a period of consolidation, the biotech sector is set to rise again based on technical analysis.
- Motley Fool•5 days ago
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Could these revolutionary therapies turn the tide in the fight against cancer?
- Motley Fool•6 days ago
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.
- InvestorPlace•7 days ago
Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
- Motley Fool•7 days ago
$50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much
Only one-third of 1% of Americans had such high prescription costs last year, but they account for more than a fifth of the spending in the category.
- Motley Fool•9 days ago
Bitcoin vs. Biotech: Which Is the Smarter Investment?
It comes down to risk vs. reward.
- Motley Fool•10 days ago
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.
- Motley Fool•10 days ago
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
A splashy acquisition puts this company on the cutting edge of cancer treatment, but that's not the only reason to buy shares.
- Zacks•11 days ago
Here's What's Has Happened in the HCV Space Lately
A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.
- Barrons.com•11 days ago
Gilead Sciences & AbbVie: Mother Always Told Me to Share
Leerink's Geoffrey Porges and Bradley Canino recently reviewed the Hepatitis C (HCV) market, and increased their price targets on Gilead (GILD) and AbbVie (ABBV) They write that both stocks are likely to enjoy a duopoly for HCV "in perpetuity," as other competitors like Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Merck (MRK) have scaled back their efforts. More from the note: After the recent announcements from JNJ (returning the rights to Achillion’s [ACHN] HCV NS5a inhibitor) and Merck (halting further development of uprifosbuvir), and the prior discontinuation of further investment into HCV at Bristol Myers after their unsuccessful investment into Inhibitex, it is now clear that the HCV category will come down to only two committed participants, Gilead and AbbVie.
- Benzinga•11 days ago
Life (Science) Lessons: The Hows And Whos To Play Biotech
Biotech is booming. After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has had “a rockstar of a year,” and the last two weeks, in particular, have ...
- Motley Fool•11 days ago
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
A streak of good news, the world's top-selling drug, and a strong pipeline. Is AbbVie simply the best biotech around?
